Lipids as biomarkers of brain disorders
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Brain is a central and pivotal organ of human body containing the highest lipids content next to adipose tissue. It works as a monitor for the whole body and needs an adequate supply of energy to maintain its physiological activities. This high demand of energy in the brain is chiefly maintained by the lipids along with its reservoirs. Thus, the lipid metabolism is also an important for the proper development and function of the brain. Being a prominent part of the brain, lipids play a vast number of physiological activities within the brain starting from the structural development, impulse conduction, insulation, neurogenesis, synaptogenesis, myelin sheath formation and finally to act as the signaling molecules. Interestingly, lipids bilayer also maintains the structural integrity for the physiological functions of protein. Thus, in light to all of these activities, lipids and its metabolism can be attributed pivotal for brain health and its activities. Decisively, the impaired/altered metabolism of lipids and its intermediates puts forward a key step in the progression of different brain ailments including neurodegenerative, neurological and neuropsychiatry disorders. Depending on their associated underlying pathways, they serve as the potential biomarkers of these disorders and are considered as necessary diagnostic tools. The present review discusses the role and level of altered lipids metabolism in brain diseases including neurodegenerative diseases, neurological diseases, and neuropsychiatric diseases. Moreover, the possible mechanisms of altered level of lipids and their metabolites have also been discussed in detail.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
The clinical symptoms of Parkinson's disease.
Sveinbjornsdottir, S. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13691 · Cited by 1,410
Dyall, S. C. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00052 · Cited by 943
Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer’s diseases
Huang, Y., & Mahley, R. W. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.025 · Cited by 829
Cholesterol metabolism and homeostasis in the brain
Zhang, J., & Liu, Q. (2015) · Protein & Cell · doi:10.1007/s13238-014-0131-3 · Cited by 686
Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation
Galvagnion, C., Buell, A. K., Meisl, G., Michaels, T. C. T., Vendruscolo, M., Knowles, T. P. J., & Dobson, C. M. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1750 · Cited by 661
Farooqui, A. A., Horrocks, L. A., & Farooqui, T. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00128-6 · Cited by 555
A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression
Lin, P.-Y., Huang, S.-Y., & Su, K.-P. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.03.018 · Cited by 530
Deregulation of sphingolipid metabolism in Alzheimer’s disease
He, X., Huang, Y., Li, B., Gong, C.-X., & Schuchman, E. H. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.010 · Cited by 516
Essential Fatty Acids and the Brain
Haag, M. (2003) · The Canadian Journal of Psychiatry · doi:10.1177/070674370304800308 · Cited by 421
Liu, J., & Wang, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01005 · Cited by 376
Omega-3 fatty acids and depression: scientific evidence and biological mechanisms
Grosso, G., Galvano, F., Marventano, S., Malaguarnera, M., Bucolo, C., Drago, F., & Caraci, F. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/313570 · Cited by 351 · cited 1×
“Finally, it is hypothesized that reduced x-3 PUFAs (DHA, EPA) and higher levels of x-6 PUFAs (AA) lower the activity of dopamine (Martins, Bentsen, and Puri 2012; Grosso et al. 2014) and contribute to the depression prognosis.”
BackgroundCholesterol: its regulation and role in central nervous system disorders
Orth, M., & Bellosta, S. (2012) · Cholesterol · doi:10.1155/2012/292598 · Cited by 339
Snowden, S. G., Ebshiana, A. A., Hye, A., An, Y., Pletnikova, O., O’Brien, R., Troncoso, J., Legido-Quigley, C., & Thambisetty, M. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002266 · Cited by 309
Brain membrane lipids in major depression and anxiety disorders
Müller, C. P., Reichel, M., Mühle, C., Rhein, C., Gulbins, E., & Kornhuber, J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.12.014 · Cited by 308
Associations Between Serum Cholesterol Levels and Cerebral Amyloidosis
Reed, B., Villeneuve, S., Mack, W., DeCarli, C., Chui, H. C., & Jagust, W. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5390 · Cited by 267
Dysregulation of lipids in Alzheimer’s disease and their role as potential biomarkers
Wong, M. W., Braidy, N., Poljak, A., Pickford, R., Thambisetty, M., & Sachdev, P. S. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.008 · Cited by 223
Thomas, J., Thomas, C. J., Radcliffe, J., & Itsiopoulos, C. (2015) · BioMed Research International · doi:10.1155/2015/172801 · Cited by 173
Lipid Biomarkers in Alzheimer's Disease
Zarrouk, A., Debbabi, M., Bezine, M., Karym, E. M., Badreddine, A., Rouaud, O., Moreau, T., Cherkaoui-Malki, M., El Ayeb, M., Nasser, B., et al. (2018) · Current Alzheimer Research · doi:10.2174/1567205014666170505101426 · Cited by 170 · cited 1×
“Their metabolism takes part in the several cellular processes including regulation of cell growth, differentiation, proliferation, apoptosis, survival, and maintenance of membrane homeostasis (Krycer et al. 2010; Zechner et al. 2012).”
BackgroundDemirkan, A., Isaacs, A., Ugocsai, P., Liebisch, G., Struchalin, M., Rudan, I., Wilson, J. F., Pramstaller, P. P., Gyllensten, U., Campbell, H., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.11.001 · Cited by 163 · cited 4×
“Most probably, increased Cer level is associated with the severity of depression (Gracia-Garcia et al. 2011; Demirkan et al. 2013) by its possible implication in apoptosis.”
BackgroundInfluentialLoss of the neuroprotective factor sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis
Couttas, T. A., Kain, N., Daniels, B., Lim, X. Y., Shepherd, C., Kril, J., Pickford, R., Li, H., Garner, B., & Don, A. S. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-9 · Cited by 161 · cited 1×
“Interestingly, sphingosine is also enhanced in parallel with AC and sphingosine-1-phosphokinases expression is downregulated (Couttas et al. 2014).”
BackgroundCholesterol metabolism in Huntington disease
Karasinska, J. M., & Hayden, M. R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.132 · Cited by 154 · cited 1×
“The mechanism by which biosynthesis of cellular cholesterol is compromised in mutant htt is due to the inhibition of SREBPs (sterol regulatory element binding proteins) and attenuated signaling of brain derived neurotrophic factor (Karasinska and Hayden 2011).”
BackgroundAltered cholesterol and fatty acid metabolism in Huntington disease
Block, R. C., Dorsey, E. R., Beck, C. A., Brenna, J. T., & Shoulson, I. (2010) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2009.11.003 · Cited by 152
Denis, I., Potier, B., Vancassel, S., Heberden, C., & Lavialle, M. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.01.007 · Cited by 150 · cited 1×
“Fatty acids particularly x-3 PUFAs are involved in the brain developments synaptogenesis and neurogenesis (Denis et al. 2013; Igarashi, Santos, and Cohen-Cory 2015).”
BackgroundPlasma lipidomics reveals potential lipid markers of major depressive disorder
Liu, X., Li, J., Zheng, P., Zhao, X., Zhou, C., Hu, C., Hou, X., Wang, H., Xie, P., & Xu, G. (2016) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-016-9768-5 · Cited by 148
Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer’s disease
Astarita, G., Jung, K.-M., Vasilevko, V., DiPatrizio, N. V., Martin, S. K., Cribbs, D. H., Head, E., Cotman, C. W., & Piomelli, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024777 · Cited by 146 · cited 1×
“In addition, the ratio of MUFAs to SFAs, which is a desaturase activity index, is stated to be negatively associated with the cognitive performance (Astarita et al. 2011).”
BackgroundLipids in the nervous system: From biochemistry and molecular biology to patho-physiology
Cermenati, G., Mitro, N., Audano, M., Melcangi, R. C., Crestani, M., De Fabiani, E., & Caruso, D. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.08.011 · Cited by 137
Wysokiński, A., Strzelecki, D., & Kłoszewska, I. (2015) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2015.04.004 · Cited by 120
Lipid metabolism in Alzheimer’s disease
Liu, Q., & Zhang, J. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1410-3 · Cited by 101
The role of oxidative stress in Huntington’s disease: Are antioxidants good therapeutic candidates?
Gil-Mohapel, J., Brocardo, P., & Christie, B. (2014) · Current Drug Targets · doi:10.2174/1389450115666140115113734 · Cited by 101
Evidence for altered cholesterol metabolism in Huntington's disease post mortem brain tissue
Kreilaus, F., Spiro, A. S., McLean, C. A., Garner, B., & Jenner, A. M. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12286 · Cited by 92
Lehto, S. M., Niskanen, L., Tolmunen, T., Hintikka, J., Viinamäki, H., Heiskanen, T., Honkalampi, K., Kokkonen, M., & Koivumaa‐Honkanen, H. (2010) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02079.x · Cited by 72
Sphingolipids in Psychiatric Disorders and Pain Syndromes
Mühle, C., Reichel, M., Gulbins, E., & Kornhuber, J. (2013) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-7091-1511-4_22 · Cited by 58
Cited by
Krämer, J., Kang, R., Grimm, L. M., De Cola, L., Picchetti, P., & Biedermann, F. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00746 · Cited by 449
Hussain, G., Wang, J., Rasul, A., Anwar, H., Qasim, M., Zafar, S., Aziz, N., Razzaq, A., Hussain, R., de Aguilar, J.-L. G., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.35653 · Cited by 323
Self-citationExploring Sphingolipid Implications in Neurodegeneration
Alessenko, A. V., & Albi, E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00437 · Cited by 141
Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers
Zorkina, Y., Ushakova, V., Ochneva, A., Tsurina, A., Abramova, O., Savenkova, V., Goncharova, A., Alekseenko, I., Morozova, I., Riabinina, D., et al. (2024) · Metabolites · doi:10.3390/metabo14020080 · Cited by 36
Li, H., Zhao, Z., Zhu, L., Tan, Y., Zhang, Z., Zhang, Z., Kang, J., Lu, H., Peng, W., & Wu, Q. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.044 · Cited by 3
Metadata
- Authors
- Hussain, G., Anwar, H., Rasul, A., Imran, A., Qasim, M., Zafar, S., Imran, M., Kamran, S. K. S., Aziz, N., Razzaq, A., Ahmad, W., Shabbir, A., Iqbal, J., Baig, S. M., Ali, M., Gonzalez de Aguilar, J.-L., Sun, T., Muhammad, A., & Muhammad Umair, A.
- Venue
- Critical Reviews in Food Science and Nutrition
- Publisher
- Informa UK Limited
- Published
- 2019-01-07
- Volume
- 60
- Issue
- 3
- Pages
- 351-374
- ISSN
- 1040-8398 (ISSN-L)
- 1549-7852
- OpenAlex
- W2910434143
- Cited by
- 103
- References
- 34
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.